FDA gave green signal to Sanofi’s Aubagio drug
The approval of Sanofi-Aventis’s Aubagio drug by the FDA (Food and Drug Administration) for treatment of relapsing forms of Multiple Sclerosis (MS) in adults is regarded to be one of the most significant clinical aspects of the drug company.
Once the drug becomes popular it is regarded to act as a highest gainer for Sanofi and it's going to act as a highly competitive drug for the existing effective drugs. As per the industry experts, the MS clinical market is around $12 billion on a yearly basis.
This teriflunomide is a once daily tablet that has been approved as an effective medication for treatment of the initial phase of the detrimental MS disease.
MS as we all know is a long-term autoimmune disease of Central nervous system that also causes inflammation of the brain along with disrupting the communication between the brain and other body parts.
Individuals with MS are found to have episodes of relapses (those results in worsening of the condition) which in turn are followed by remissions (recovery).
The side effects that were reported by the drug are hair loss, diarrhea, nausea, abnormal liver test, etc. and hence, it is regarded to be taken only after consultation with your medical professional.
The precautionary measures that should be followed include avoiding the drug in case you suffer from any delirious clinical conditions of the liver, in case you are a pregnant woman, etc.
Also, stay away from it as it is found to cause birth defects in some cases and may also prove fatal in some extreme cases.
Tags: FDA , Drug Company , Delirious Clinical Condit , Drug
This work is licensed under a Creative Commons Attribution-No Derivative Works 3.0 License.